Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin

Targeted anti-vascular therapies for ovarian cancer: current evidence

(2013) M Hall et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation

(2013) Min Dai et al.   JOURNAL OF IMMUNOTHERAPY

Advances in targeting cell surface signalling molecules for immune modulation

(2013) Sheng Yao et al.   NATURE REVIEWS DRUG DISCOVERY

Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum

(2012) Ahmed Y. Ali et al.   Annals of the New York Academy of Sciences

Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies

(2012) I. Verbrugge et al.   CANCER RESEARCH

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

(2012) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen

(2012) Renee Vermeij et al.   CURRENT PHARMACEUTICAL DESIGN

Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis

(2012) Huafeng Wei et al.   GYNECOLOGIC ONCOLOGY

Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma

(2012) Qinghua Feng et al.   GYNECOLOGIC ONCOLOGY

Immunotherapy earns its spot in the ranks of cancer therapy

(2012) Drew Pardoll et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Silencing of the TGF-β1 Gene Increases the Immunogenicity of Cells From Human Ovarian Carcinoma

(2012) Huafeng Wei et al.   JOURNAL OF IMMUNOTHERAPY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy in ovarian cancer

(2012) Gina M. Mantia-Smaldone et al.   Human Vaccines & Immunotherapeutics

Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer

(2011) J. Krempski et al.   JOURNAL OF IMMUNOLOGY

Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer

(2011) Grazia Graziani et al.   PHARMACOLOGICAL RESEARCH

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

Immunotherapy for Ovarian Cancer: What's Next?

(2010) Lana E. Kandalaft et al.   JOURNAL OF CLINICAL ONCOLOGY

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY

Cancer Immunotherapy Using In vitro Genetically Modified Targeted Dendritic Cells

(2008) H. Wei et al.   CANCER RESEARCH

Combination Therapy with Cisplatin and Anti-4-1BB: Synergistic Anticancer Effects and Amelioration of Cisplatin-Induced Nephrotoxicity

(2008) Y. H. Kim et al.   CANCER RESEARCH

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice

(2008) James O. McNamara et al.   JOURNAL OF CLINICAL INVESTIGATION